Journal of Internal Medicine Concepts & Practice››2021,Vol. 16››Issue (02): 131-133.doi:10.16138/j.1673-6087.2021.02.014
• Case report •Previous ArticlesNext Articles
Received:2020-01-03Online:2021-04-25Published:2022-07-26| [1] | Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(6): 982-990. doi:10.1016/j.bbmt.2016.01.013URL |
| [2] | Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis[J]. Leukemia, 2005, 19(8): 1345-1349. pmid:15959528 |
| [3] | Small D. FLT3 mutations: biology and treatment[J]. Hematology Am Soc Hematol Educ Program, 2006: 178-184. |
| [4] | Port M, Böttcher M, Thol F, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis[J]. Ann Hematol, 2014, 93(8): 1279-1286. doi:10.1007/s00277-014-2072-6pmid:24801015 |
| [5] | Chang P, Kang M, Xiao A, et al. FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia[J]. BMC Cancer, 2010, 10: 513-519. doi:10.1186/1471-2407-10-513URL |
| [6] | Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults withde novocytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications[J]. Blood, 2008, 111(3): 1552-1559. doi:10.1182/blood-2007-08-107946pmid:17940205 |
| [7] | Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients[J]. Blood, 2008, 111(5): 2527-2537. doi:10.1182/blood-2007-05-091215URL |
| [8] | Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis[J]. Ther Adv Hematol, 2017, 8(9): 245-261. doi:10.1177/2040620717721459pmid:29051803 |
| [9] | Rossi G, Minervini MM, Carella AM, et al. Wilms’tumor gene(WT1) expression and minimal residual disease in acute myeloid leukemia//van den Heuvel-Eibrink MM. Wilms tumor[M]. Brisbane(AU): Codon Publications, 2016: 273-280. |
| [10] | Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation[J]. Leuk Res, 2012, 36(4): 453-458. doi:10.1016/j.leukres.2011.09.005URL |
| [11] | Polák J, Hájková H, Maalaufová-Soukupová J, et al. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression[J]. Exp Ther Med, 2012, 3(1): 129-133 doi:10.3892/etm.2011.363URL |
| [12] | Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia[J]. PLoS One, 2014, 9(3): e92470. doi:10.1371/journal.pone.0092470URL |
| [13] | Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia[J]. J Clin Oncol, 2009, 27(31): 5195-5201. doi:10.1200/JCO.2009.22.4865URL |
| [14] | Roskoski R Jr. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies[J]. Pharmacol Res, 2016, 113(85): 395-408. doi:10.1016/j.phrs.2016.09.011URL |
| [15] | Zidan MA, Kamal Shaaban HM, Elghannam DM. et al. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype[J]. Hematology, 2014, 19(5):267-274. doi:10.1179/1607845413Y.0000000129URL |
| [1] | GAO Caihong.Analysis of therapeutic efficacy of simplified diagnosis and treatment for outpatients with acute mild ischemic stroke in designated hospitals during the COVID-19 pandemic[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 385-389. |
| [2] | JIANG Tianyi, LIU Fujia, CHENG Wenyan, ZHAO Huijin, SHEN Yang.Recombinant human thrombopoietin in treatment of acute myeloid leukemia thrombocytopenia after chemotherapy: a real-world study[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 283-288. |
| [3] | .[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 353-355. |
| [4] | LUO Dongfeng, YOU Jianhua, LI Xiaoyang, LI Junmin, ZHANG Yunxiang.Study on the efficacy and safety of different induction therapies in newly diagnosed elderly patients with acute myeloid leukemia and intolerance of intensive chemotherapy[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 220-226. |
| [5] | .[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 253-255. |
| [6] | .[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 282-286. |
| [7] | HUANG Lei, YE Chenjing, WU Chao, XU Wenbin, YU Qing, LI Junmin, YAN Hua.Clinical observation of the combination therapy of azacitidine and venetoclax in newly diagnosed, elderly patients with acute myeloid leukemia[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(03): 178-182. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
